Form 4: TriSalus CFO David Patience Granted Equity Awards

TriSalus Life Sciences, Inc. Chief Financial Officer David Patience received grants of 200,000 restricted stock units and 290,000 employee stock options.

Summary

• David Patience, Chief Financial Officer of TriSalus Life Sciences, Inc. (TLSI), was granted 200,000 shares of common stock in the form of Restricted Stock Units (RSU Award).
• The RSU Award vests in four equal annual installments, commencing on July 1, 2026, contingent on Mr. Patience's continued service.
• Mr. Patience also received a grant of 290,000 employee stock options with an exercise price of $3.88 per share.
• The stock options begin vesting on the one-year anniversary of July 1, 2026, with one-fourth of the shares vesting then, and 1/36th of the remaining shares vesting monthly thereafter, subject to continuous service.
• The transaction date for both grants was August 14, 2025.

Sentiment

Score: 7

Explanation: The filing indicates a standard executive compensation event, which is generally positive as it aligns management incentives with shareholder interests, promoting long-term value creation and executive retention. It does not contain negative financial news or significant operational setbacks.

Positives

• The equity grants align the Chief Financial Officer's interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedules for both RSUs and stock options promote executive retention by requiring continued service over several years.

Negatives

• The issuance of new equity awards, while common, can lead to minor dilution for existing shareholders over time as shares vest and options are exercised.

Risks

• The value of the RSU Award and stock options is subject to the future market price of TriSalus Life Sciences, Inc. common stock, which may fluctuate.
• Vesting of the awards is contingent on the Reporting Person's continued service, meaning forfeiture if employment ceases before vesting dates.

Future Outlook

The vesting schedules for the RSU Award and employee stock options extend through July 2026 and beyond, indicating a long-term incentive structure tied to the Chief Financial Officer's continued service and the company's future performance.

Industry Context

Equity grants, including Restricted Stock Units and stock options, are standard components of executive compensation packages in the life sciences industry, aiming to attract, retain, and motivate key personnel by aligning their financial interests with the company's long-term success and shareholder value creation.

Comparison to Industry Standards

• The use of both Restricted Stock Units (RSUs) and stock options is a common practice in executive compensation across the biotechnology and life sciences sectors, similar to compensation structures seen at companies like Moderna or BioNTech, which utilize a mix of cash and equity.
• The multi-year vesting schedule (four equal annual installments for RSUs, and a one-year cliff followed by monthly vesting for options) is typical for executive equity awards, comparable to vesting schedules at peer companies such as Gilead Sciences or Amgen, designed to ensure long-term retention and performance alignment.
• The grant of 200,000 RSUs and 290,000 options to a CFO is within the expected range for a company of TriSalus Life Sciences' profile, though specific comparisons would require detailed analysis of the company's market capitalization, revenue, and the executive's overall compensation package relative to industry benchmarks.

Stakeholder Impact

• Shareholders: The grants align the CFO's interests with shareholder value creation, but also introduce minor potential for future dilution.
• Employees: The compensation structure for a key executive may set a precedent or reflect the company's overall approach to incentivizing its workforce.
• Management: The grants provide significant long-term incentives and retention for the Chief Financial Officer.

Next Steps

• The RSU Award will begin its vesting schedule on July 1, 2026, with subsequent annual vesting installments.
• The employee stock options will begin their vesting schedule on the one-year anniversary of July 1, 2026, followed by monthly vesting.

Key Dates

Keywords

TriSalus Life Sciences, TLSI, SEC Form 4, Restricted Stock Units, Employee Stock Options, Equity Grant, Executive Compensation, Insider Transaction, David Patience